Nöroloji

Yazarlar

Alp Sarıteke

Özet

Bu çalışma, serebrovasküler hastalıklar (özellikle iskemik inme) ve Alzheimer hastalığının tanı, risk faktörleri ve tedavi yaklaşımlarını incelemektedir. İnme; iskemik (%85) ve hemorajik olarak ikiye ayrılır. Yaş, genetik, hipertansiyon, diyabet, obezite, atriyal fibrilasyon, sigara ve fiziksel inaktivite inmenin ana risk faktörlerindendir. Akut iskemik inmede beyin BT ilk tercih edilen görüntüleme yöntemidir; tedavi sürecinde ilk 4,5 saatte uygulanan intravenöz trombolitik (r-tPA) tedavi ile endovasküler girişimler kritik öneme sahiptir. Ayrıca rekürrensi önlemek adına Asetilsalisilik Asit (ASA) ve klopidogrel gibi antiagreganlar ile duruma göre antikoagülan tedaviler kullanılır. TOAST sınıflamasına göre iskemik inmeler; büyük arter aterosklerozu, kardiyoembolizm, küçük damar oklüzyonu, belirlenen diğer nedenler ve nedeni bilinmeyenler olmak üzere beş gruba ayrılır. Demans vakalarının %60'ını oluşturan Alzheimer hastalığında ise yaş en önemli risk faktörüdür. Tamamen iyileştiren bir tedavi bulunmamakla birlikte; hafif-orta evrede kolinesteraz inhibitörleri (donepezil, rivastigmin, galantamin), orta-ağır evrede ise NMDA antagonisti (memantin) kullanılır. Ek olarak egzersiz, semptomatik psikiyatrik tedaviler ve palyatif bakım hastaların yaşam kalitesini artırmada önemli rol oynar.

Referanslar

Sacco RL, Kasner SE, Broderick JP, et al. An Updated Definition of Stroke for the 21st Century. A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2013;44: 2064-89.

Arsava M. Beyin Damar Hastalıkları ve Demans. Ulusal Hastalık Yükü Çalışması Sonuçları ve Çözümleri 2017.

Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology 2015;45(3): 161-76.

Boehme AK, Esenwa C, Elkind MS. Stroke Risk Factors, Genetics and Prevention. Circ Res 2017;120(3): 472-95.

Mikulik R, Wahlgren N. Treatment of acute stroke: an update. J Intern Med. 278: 145-65.

Meschia JF, Bushnell C, Boden Albala B, et al. Guidelines fort he primary prevention of stroke. A Statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2014;45: 3754-3832.

Kuklina EV, Tong X, George MG, et al. Epidemiology and prevention of stroke: a worldwide perspective. Expert Rev Neurother 2012;12(2): 199-208.

Perkovic V, Rodgers A. Redefining blood pressure targets: SPRINT starts the marathon. N Engl J Med. 2015;373: 2175-8.

Banerjee C, Moon YP, Paik MC, et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. Stroke. 2012;43: 1212-17.

0’Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case control study. Lancet 2016;388(10046): 761-75.

0’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 countries (INTERSTROKE): a case control study. Lancet 2010;376(9735): 112-23.

Yusuf, Hawken S, Ounpuu S, et al. Interheart study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART study): case control study. Lancet 2004;364(9438): 937-52.

Guzik A, Bushnell C. Stroke epidemiology and risk factor management. Continuum. Cerebrovascular disease 2017;23: 15-39.

Lip GYH, Tse HF, Lane DA. Atriyal fibrillation. Lancet 2012;379: 648-61.

Ceornodolea AD, Bal R, Severens JL. Epidemiology and Management of Atriyal Fibrillation and Stroke: Review of Data from Four European Countries. Stroke Res Treat 2017;2017: 8593207.

Feigin VL, Roth GA, Naghavi M, et al. Global Burden of Diseases, Injuries and Risk Factors Study 2013 and Stroke Experts Writing Group. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 2016;15(9): 913-24.

Martinez-Gonzalez MA, Dominguez LJ, Delgado-Rodriguez M. Olive oil consumption and risk of CHD and/or stroke: a metaanalysis of case conrtol, cohort and intervention studies. Br J Nutr 2014;112: 248-59.

Lee KK, Miller MR, Shah ASV. Air Pollution and Stroke. J Stroke 2018;20(1): 2-11.

Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definition for use in a multicenter clinical trial. Stroke. 1993;24: 35-41.

Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ 2020;368: I6983.

T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Akut İskemik İnme Tanı ve Tedavi Rehberi 2020.

Jovin TG, Chamorro A, Cobo E, et al. REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372: 2296–2306.

Campbell BC, Mitchell PJ, Kleinig TJ, et al. EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372: 1009-18.

Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke 2018;49: e46-e110.

Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1): 59-70.

Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289: 210-16.

Briggs R, Kennelly SP, O’Neill D. Drug treatments in Alzheimer’s disease. Clin Med 2016;16(3): 247-53.

Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomised controlled trial. JAMA 2003;290: 2015-22.

Matis GK, Birbilis T. The Glasgow Coma Scale – A brief review. Past, present, future. Acta neurologica belgica 2008; 108:75-89.

Yayınlanan

5 Ocak 2022

Lisans

Lisans